Please login to the form below

Not currently logged in
Email:
Password:

Consilium wins Allergy Therapeutics account

Will advise the firm on international investor relations

Consilium Strategic CommunicationsConsilium Strategic Communications has been appointed by specialty pharmaceutical firm Allergy Therapeutics as its international investor relations advisor.

The healthcare agency will support Allergy Therapeutics' international financial and corporate public relations activities as it seeks to step up its international stakeholder activities.

Consilium's Mary-Jane Elliott, Chris Gardner, Ivar Milligan, Matthew Neal and Laura Thornton have been tasked with raising the European allergy product company's global profile, particularly focusing on the US.

Commenting on the Consilium advisory team, Allergy Therapeutics' chief executive officer Manuel Llobet said: “This team's expertise and knowledge of the sector is unrivalled and they have already demonstrated this through their high quality advice, proactivity and professionalism.”

Elliott, co-founder and managing partner at Consilium, said: “We are delighted to be advising Allergy Therapeutics at a time when they are on a steep growth trajectory due to a strong portfolio of marketed products and M&A.

“We look forward to accompanying them on their journey as they pave the way to the US market and further international growth.”

Article by
Rebecca Clifford

7th March 2016

From: Marketing

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

We love what we do and we think it shows.It shows in the work we do, the space we work...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics